Imagine a world where doctors can predict how a tumor will respond to treatment before a patient begins therapy.
The story of cancer research is a story of evolution, not only of the disease itself but of our understanding. For decades, cancer was studied in simplified systems that failed to capture the living complexity of human tumors. Then came waves of innovation. The genomic revolution revealed the immense diversity of mutations and molecular alterations driving tumor growth, metastasis, and resistance.
Public resources like The Cancer Genome Atlas (TCGA) seemed to promise the ultimate breakthrough, a molecular codebook of cancer . Yet this progress revealed an important blind spot: most TCGA data come from untreated primary tumors [1]. As therapies have advanced and patients now receive multiple lines of treatment, the biology of pretreated, therapy-exposed tumors has become one of the most critical and least understood frontiers in oncology.
Understanding that biology is not just a scientific goal but an ethical imperative. Cancer is not a single disease; it is a dynamic, adaptive system shaped by genetics, the tumor microenvironment, and therapeutic history. If we are to fulfill the promise of precision medicine, we must move beyond isolated biomarkers and study tumors as evolving ecosystems.
What if we could predict response before treatment begins? What happens when molecular data meet biologically realistic tumor models that reflect not only tumor biology but also the diversity of real patients?
From Genomics to Real-World Tumor Modeling
When molecular data meet functional biology, each gains meaning. This is where patient-derived xenograft (PDX) models transform translational research [2][3]. Unlike cell lines or standard treatment-naïve PDXs, pretreated PDXs are established from tumors that have already been exposed to therapies such as targeted drugs, chemotherapies, immunotherapies, or combinations. These models carry within them the molecular “scars” of prior treatments: resistance pathways, adaptive rewiring, and the phenotypic heterogeneity that defines today’s clinical population.
These models do more than represent tumor biology—they mirror the clinical reality of modern oncology. Pretreated PDXs function as renewable, living repositories of human disease that evolve alongside new technologies. Beyond their value for molecular characterization, their power lies in versatility, enabling hypothesis testing, target validation, synergy exploration, and modeling of therapeutic resistance in real time [2][3].
Champions Oncology’s pretreated PDX cohort extends this concept into a fully integrated translational framework. By correlating pharmacologic responses with molecular and phenotypic data, these models provide a means to explore how tumors that have evolved under today’s therapies might respond to tomorrow’s drugs, effectively using the biology of resistance to anticipate future sensitivity.
This integration of pharmacologic and phenomic data represents a paradigm shift: transforming living models of resistant disease into predictive engines that can forecast therapeutic response before clinical relapse. It bridges the gap between molecular information, biological function, and patient reality, advancing precision medicine from observation to anticipation.
European research programs have long emphasized the need for such realism. Horizon Europe initiatives, for example, promote translational fidelity while encouraging reductions in animal use through better model selection. Pretreated models achieve both: they more closely mirror real patient populations and, by improving predictivity, help reduce redundant in vivo experimentation.
Refinement in Practice: Organoids and 3D Tumor Systems
A vital bridge between living tumor models and computational prediction is the rise of ex vivo organoid systems, three-dimensional cultures that capture the complexity of patient tumors in a scalable and experimentally tractable form. These systems enable high-throughput functional testing while preserving the tumor’s structure, microenvironment, and therapeutic history [4].
When combined with genomic and pharmacologic data from pretreated PDXs, ex vivo organoids create the foundation for what many now call “digital patients”, biologically grounded computational avatars capable of simulating therapeutic response.
The importance of these 3D systems has been formally recognized by international agencies such as the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) and the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) [5]. Both endorse advanced 3D tumor models as scientifically robust alternatives to traditional animal studies, improving human relevance while reducing animal use.
The predictive value of these digital frameworks depends entirely on the fidelity of the underlying biology. Algorithms are only as accurate as the datasets that train them, and those datasets must represent the biology of today’s therapy-exposed patients, not historical untreated cases.
By anchoring computational models in pretreated, phenotypically diverse tumor systems, researchers can begin to generate predictive insights that inform both clinical decision-making and the design of next-generation therapies.
Data Integration and Ethical Innovation
The value of these integrated datasets extends beyond any single study. By combining molecular, phenotypic, and functional data within well-annotated, traceable patient-derived models, this approach aligns with FAIR data principles, assuring that scientific information is Findable, Accessible, Interoperable, and Reusable.
This vision echoes major European initiatives such as the European Open Science Cloud (EOSC) and ELIXIR, which promote open, harmonized frameworks for biomedical data sharing [6].
In this context, Champions Oncology’s datasets represent more than proprietary collections. They form a resource designed for interoperability, transparency, and predictive innovation. Each model and dataset contributes to a larger ecosystem where information can be integrated, compared, and algorithmically analyzed to accelerate discovery.
Toward Adaptive and Ethical Prediction
The convergence of biology, data, and computation sets the stage for a new generation of adaptive clinical trials, frameworks where preclinical and computational evidence continuously refine trial design. These models enable real-time optimization of patient cohorts, dosing strategies, and therapeutic combinations based on evolving biological insights. Pretreated PDX and ex vivo systems become experimental testbeds that mirror ongoing clinical dynamics, closing the loop between prediction, experimentation, and patient care.
Yet as the field races toward prediction, it’s essential to remember that models, digital, ex vivo, or in vivo, are reflections of biology, not replacements for it. Predictive algorithms accelerate discovery, but their accuracy depends on the fidelity of the biology they represent.
Validation in robust in vivo systems, especially those that capture the diversity and complexity of human disease, remains critical to confirm translational hypotheses. The future of oncology will not belong to any single model or dataset, but to their integration from the petri dish to the patient.
Perhaps the real frontier is not in building systems that outperform biology, but in creating ones that understand it. When every dataset, model, and algorithm is grounded in the lived biology of patients, prediction becomes more than computation; it becomes empathy, encoded in data.
References
[1] National Cancer Institute, The Cancer Genome Atlas (TCGA). ‘TCGA Program Overview’ and ‘Cancers Selected for Study.’ last accessed in December 2025.
[2] Slyskova J, et al. Role of Patient-Derived Models of Cancer. Translational Oncology. Cancers. 2023;15(1):139.
[3] Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022 May 10;20(1):206. doi: 10.1186/s12967-022-03405-8. PMID: 35538576; PMCID: PMC9088152.
[4] Gao J, Lan J, Liao H, Yang F, Qiu P, Jin F, Wang S, Shen L, Chao T, Zhang C, Zhu Y. Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges. BMC Cancer. 2023 Dec 7;23(1):1205. doi: 10.1186/s12885-023-11434-9. PMID: 38062430; PMCID: PMC10702130.
[5] Gribaldo L, Dura A. EURL ECVAM Literature Review Series on Advanced Non-Animal Models for Respiratory Diseases, Breast Cancer and Neurodegenerative Disorders. Animals (Basel). 2022 Aug 25;12(17):2180. doi: 10.3390/ani12172180. PMID: 36077900; PMCID: PMC9454965.
[6] EOSC4Cancer Consortium. European Open Science Cloud for Cancer (EOSC4Cancer). 2022–2025.
Featured image: Caregiver supporting a sick cancer patient. Photo courtesy: © Fotolia/Adobe 2017 – 2025. Used with permission.
DOI
